We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
The Treatment of Long COVID with Chinese Medicine: A Case Report
Did you know?
For the cost of 5 articles (students) or 10 articles (practitioners) you can buy a year's access to the entire Journal of Chinese Medicine article archive.
£4.00
VAT Exempt
In stock
SKU
JCM127/17
Long COVID is a relatively new disorder that is marked by chronic health complications following an acute infection of COVID-19. Approximately 10 per cent of people that contract SARS-CoV-2 continue to be in
poor health three weeks after the initial onset. Currently, there are no standardised treatment methods for those suffering with long COVID due to the marked variation between individual experiences. The subject
of the study suffered with gastrointestinal pain, distention and irritable bowel for four months after initial infection. After using a combination of acupuncture and Chinese herbal medicine, the patient’s pain disappeared, the stools became formed and regular and distention was minimal. This case illustrates the possibility of using traditional Chinese medicine (TCM) as a viable treatment for long COVID.
poor health three weeks after the initial onset. Currently, there are no standardised treatment methods for those suffering with long COVID due to the marked variation between individual experiences. The subject
of the study suffered with gastrointestinal pain, distention and irritable bowel for four months after initial infection. After using a combination of acupuncture and Chinese herbal medicine, the patient’s pain disappeared, the stools became formed and regular and distention was minimal. This case illustrates the possibility of using traditional Chinese medicine (TCM) as a viable treatment for long COVID.
Author | Candace Jania |
---|---|
JCM Issue | JCM127/17 |
Write Your Own Review
* Orders shipped outside of Europe are eligible for VAT relief and will not be charged VAT.